(Lymphoma) FDA Approves CAR-T Therapy Breyanzi
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- April 19, 2021
- Read time: 1 minute
On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's CAR-T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel) for patients with relapsed or refractory large B-cell lymphoma. This is the third gene therapy approved by the FDA for diffuse large B-cell lymphoma and certain types of non-Hodgkin's lymphoma.
It is indicated for patients with diffuse large B-cell lymphoma and certain types of non-Hodgkin's lymphoma who have received two or more prior systemic therapies with poor outcomes or relapse after treatment. It is not indicated for patients with CNS lymphoma. The FDA has designated it as an Orphan Drug, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT).
Due to potential adverse events such as cytokine release syndrome (CRS) or neurological toxicity, close attention will be paid to whether relevant medical institutions comply with Risk Evaluation and Mitigation Strategy (REMS) requirements. The FDA will evaluate long-term safety and has required manufacturers to conduct post-market observational studies.
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma in adult patients. In the United States, approximately 77,000 new cases of non-Hodgkin's lymphoma are diagnosed annually, of which one-third are diagnosed as diffuse large B-cell lymphoma.
Source: https://www.mixonline.jp/tabid55.html?artid=70614
- Immunotherapy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4